Myocardial fibrosis (MF) is a common phenomenon in the late stages of diverse cardiac diseases and is a predictive factor for sudden cardiac death. Myocardial fibrosis detected by magnetic resonance imaging has also been reported in athletes. Regular exercise improves cardiovascular health, but there may be a limit of benefit in the exercise dose-response relationship. Intense exercise training could induce pathologic cardiac remodeling, ultimately leading to MF, but the clinical implications of MF in athletes are unknown. For this comprehensive review, we performed a systematic search of the PubMed and MED-LINE databases up to June 2016. Key Medical Subject Headings terms and keywords pertaining to MF and exercise (training) were included. Articles were included if they represented primary MF data in athletes. We identified 65 athletes with MF from 19 case studies/series and 14 athletic population studies. Myocardial fibrosis in athletes was predominantly identified in the intraventricular septum and where the right ventricle joins the septum. Although the underlying mechanisms are unknown, we summarize the evidence for genetic predisposition, silent myocarditis, pulmonary artery pressure overload, and prolonged exercise-induced repetitive micro-injury as contributors to the development of MF in athletes. We also discuss the clinical implications and potential treatment strategies of MF in athletes.
C ardiac remodeling is a common adaptation in trained athletes that consists of increased left ventricular (LV) and right ventricular (RV) dimensions and atrial cavity size and is associated with normal systolic and diastolic function. 1, 2 The increase in cardiac dimensions typical of an athlete's heart facilitates an increase in stroke volume and cardiac output during exercise. 3 It is generally accepted that exercise benefits cardiovascular health, 4 but myocardial fibrosis (MF) has been detected in endurance athletes by cardiac magnetic resonance imaging (CMR) using late gadolinium enhancement (LGE). [5] [6] [7] [8] [9] [10] [11] Myocardial fibrosis is defined by a significant increase in the collagen volume of myocardial tissue. It is a complex process that involves all components of the myocardial tissue and can be triggered by tissue injury from myocardial ischemia (hypoxia), inflammation, and hypertensive overload. 12 Fibrosis generally occurs with cardiac remodeling secondary to diseases such as heart failure, hypertension, and valvular dysfunction. 13 Myocardial fibrosis leads to increased myocardial stiffness, 14 which increases LV end-diastolic and left atrial pressures.
In animal models and patient studies, MF is also associated with reduced ventricular systolic function. 15 Patients with MF have a higher incidence of ventricular arrhythmias 16, 17 and more adverse cardiac outcomes. 18 Not all endurance athletes demonstrate MF, [19] [20] [21] [22] [23] making the relationship between lifelong endurance exercise and the development of MF unclear. Furthermore, the clinical implications of MF in athletes are unknown. This systematic review summarizes the available data on the prevalence of MF in physically active individuals to identify predictors and the potential mechanism(s) of MF development and its clinical implications.
METHODS

MF Assessment
Myocardial fibrosis can be determined by microscopic examination of tissue samples or by CMR. Myocardial tissue is obtained in vivo by transvenous endomyocardial biopsy of the RV. Fibrillar collagen can then be quantified under polarized light after Picrosirius red 24 or Masson trichrome 25 staining. Using CMR to assess LGE, a sign of MF, is preferred for assessment of focal MF because it is readily available, is noninvasive, and has the capacity to assess all the cardiac chambers. Alternatively, CMR-based contrast-enhanced T1 mapping can be used to assess diffuse MF. 26, 27 Search Strategy We performed a systematic search of peerreviewed studies that examined MF in athletes using cardiac biopsy or CMR. The literature was searched using the PubMed and MEDLINE databases up to June 1, 2016 . Key Medical Subject Headings terms and keywords were included pertaining to MF (delayed [gadolinium] enhancement, pathological late gadolinium enhancement, myocardial late gadolinium enhancement, abnormal late gadolinium enhancement, fibrosis, myocardium, myocardial fibrosis, papillary muscles/pathology, ventricular dysplasia, and ventricular torsion) and exercise training (exercise, athletes, sports, sport, motor activity, marathon, triathlon, bicycling, swimming, physical endurance, marathon running, sports medicine, and exercise-induced).
Selection of Studies
The selection process consisted of review of the titles, abstracts, and full texts of articles by two authors (F.R.S. and T.M.H.E.), who later met to reach mutual consensus. The inclusion criteria were (1) fibrosis established by validated techniques and (2) a study population consisting of athletes, defined as "individuals who are proficient in sports, have routinely performed exercise training for an extended period of time and participate in sporting events." The only exclusion criteria was underlying (genetic) cardiovascular disease, such as hypertrophic cardiomyopathy or arrhythmogenic RV cardiomyopathy.
RESULTS
The systematic search yielded 33 studies: 19 case reports/series using biopsy (n¼17) and CMR (n¼2) to determine MF and 14 studies in athletic populations using CMR to determine MF (Figure 1 ).
MF Reported in Case Studies/Series
Case reports/series included 35 athletes (Table 1) participating in a wide range of sports: orienteering, 33 powerlifting, 38 basketball, 46 volleyball, 31 waterskiing, 31 soccer, 28, 31, 34, 37, 44 (marathon) running, 29, 30, 34, 39, 42 cycling, 45, 46 and triathlon. 40 To our knowledge, the first report of MF in athletes was published in 1983 and described MF in a soccer player. 28 Athletes ranged in age from 13 to 73 years at MF diagnosis, and 76% of the population was male. Although the sex and age of 6 athletes was not reported, 35, 41 most athletes with MF were young (20 of 35 were aged 30 years). In 12 athletes (34%), the biopsies were performed postmortem.
MF Reported in Athletic Populations
The existence of MF was also assessed by CMR in athletic populations ( Table 2) . A total of 509 endurance exercise athletes were examined; 7 studies confirmed the presence of MF in athletes, and 7 studies did not. Overall, 89% of the population was male, and MF was reported in 30 of the 509 athletes (5.9%). Interestingly, lifetime exercise exposure (1-100 completed marathons) and age (26-72 years) varied substantially across participants, but most reports occurred in long-term endurance athletes.
ARTICLE HIGHLIGHTS
n Habitual physical activity is known to reduce the risk of future cardiovascular morbidity and mortality. Several studies exploring the relationship between physical activity and cardiovascular health have reported a curvilinear association. However, emerging evidence suggests that cardiac maladaptations may occur in a few endurance athletes who perform exercise at the upper end of the physical activity continuum. Among other observations (ie, enhanced coronary artery calcification, cardiac dysfunction, cardiac biomarker release, and arrhythmias), evidence of myocardial fibrosis (MF) has been reported in case reports and athletic population studies.
n Typically, MF is observed in cardiac patients and is a predictive factor for adverse cardiac outcome, such as sudden cardiac death. Whether the development of MF in athletes is related to their exercise training and competition regimens or is secondary to (subclinical) cardiovascular disease is key because this provides essential insight into the underlying mechanisms.
n Characterization of the phenotype of MF is important to allow early identification of athletes at risk. Furthermore, the pattern, location, and quantification of MF may importantly drive the choice of specific treatment strategies and lifestyle advice.
Patterns, Location, and Quantification of MF
The pattern of MF in athletes determined by microscopic examination varies (Table 1) , and this likely represents different causes. Fourteen of the 35 athletes with MF (40%) included in the case reports/series demonstrated a nonspecific LGE pattern, and the remaining athletes demonstrated an ischemic (n¼7, 20%), myocarditic (n¼7, 20%), or hypertrophic (n¼1, 3%) MF pattern; the pattern was not specified in 6 athletes (17%) ( Figure 2 ). Findings from the CMR studies confirm the variation in MF patterns ( Table 2 ). Most athletes with MF (12 of 30, 40%) show a nonspecific LGE pattern. 5, 7, 11 A subendocardial pattern, typically seen after ischemic myocardial injury because the subendocardium is the region most vulnerable to reduced coronary blood flow, was observed in 8 of 30 athletes with MF (27%). 5, 7, 9 There are also several reports of probable scarring from myocarditis (n¼3, 10%) and mechanical overload (n¼7, 23%) ( Figure 2 ). 5, 8, 10, 11 The location of MF determined by biopsy (case studies/series) and CMR-LGE (athletic population studies) varies substantially ( Figure 3 ). La Gerche et al 6 reported that MF was confined to the interventricular septum, frequently where the RV attaches to the septum (the hinge points). Overall, a significant proportion of MF in athletes is found in the septum (19 of 65, 29%) 5,6,34,41e43 and RV insertion points (12 of 65, 19%). 5 Some have speculated that the distention of the RV during endurance exercise due to an acute increase in RV work with exercise may be responsible for this interventricular scar pattern. 6 The quantification of MF is poorly reported: only 3 case reports and 1 CMR study describe the extent of fibrosis. The volume of the scar in a biopsy taken from a runner confirmed that MF was present in 2.9% of the LV and 3.5% of the interventricular septum. 34 In another case it was reported that approximately 25% of the myocardium was involved in some kind of MF. 38 Breuckmann et al 7 reinforced the heterogeneity of the percentage of LGE-positive myocardium (range, 0.5%-17.8%) in German marathon runners. Also, these authors found that the median percentage of MF was comparable between runners with a subendocardial LGE pattern (0.9%), runners with a nonspecific pattern (1.2%), and physically inactive controls (2.2%). Last, the mean AE SD volume of the LGE region in the study by Schnell et al 46 was 20.3AE7.7 g, which was the equivalent of 12%AE4.8% of the LV mass.
DISCUSSION
The present review reveals that the phenotype of MF in athletes demonstrates large variance in patterns, location, and quantification. Nonetheless, a nonspecific LGE pattern, location in the RV or septum, and representing 1% to 3% of the myocardium seem to be the most common descriptors used for MF typically found in athletes by magnetic resonance imaging. The phenotype of MF in athletes differs from that in the general population, and this difference may provide insight into the underlying mechanisms and clinical prognosis of MF in assumingly healthy athletes.
MF in Athletes vs Controls
The prevalence of MF varied from 0% to 50% in often small-scale athlete populations. Only 2 studies compared MF prevalence between athletes and age-and sex-matched physically inactive controls. 5, 7 Breuckmann et al 7 found that MF was more prevalent in athletes (n¼102) than in controls (n¼102) (12% vs 4%; P¼.077). Wilson et al 5 observed MF in 6 of 12 lifelong veteran endurance athletes but not in any of 20 sedentary peers. Although both studies reported a higher prevalence of MF in athletes vs physically inactive controls, the presence of MF in these control groups was lower compared with recent observations in the general population. In a large American cohort study of nonathletes (mean AE SD age, 68AE9 years), MF was found in 146 of 1840 participants (7.9%). 48 Population studies from Iceland (n¼936) 49 and Sweden (n¼248) 50 report an even higher prevalence of unknown MF (17.0% and 19.8%, respectively). These findings highlight the need for additional high-quality studies comparing the prevalence and extent of MF in large populations of physically active and inactive individuals. Future studies should consider the amount and intensity of exercise training, as well as the lifelong exercise exposure, to test the hypothesis that MF prevalence differs between athletes and the general population.
Focal vs Diffuse MF
The CMR studies assessing MF in athletes included predominantly LGE measurements. Although CMR-LGE is a validated technique to assess quantification of focal MF, it does not provide information about the presence of diffuse MF. This may lead to underestimating the true prevalence of MF in athletes and may limit the generalizability of these findings.
Nevertheless, 2 recent studies used T1 and T2 mapping to assess (diffuse) MF in athletes. 8, 51 In a Scottish study, no difference in native T1, T2 relaxation time and extracellular volume was observed between athletes (n¼21, !6 h/wk of exercise training) and controls (n¼21). 8 In contrast, significantly higher native T1 values of the LV and interventricular septum were found in Turkish athletes (!6 h/wk intense exercise training) compared with age-and sex-matched controls (<3 h/wk moderate exercise). Moreover, athletes reporting at least 5 years of exercise training had higher T1 values, indicating more diffuse fibrosis compared with athletes exercising for less than 5 years (P<.05). 51 These findings suggest a higher prevalence of diffuse MF in Turkish athletes vs controls. Apart from the age difference between Scottish (mean AE SD age, 46AE11 years) and Turkish (mean AE SD age, 25AE3 years) athletes, there is no clear explanation for the conflicting outcomes. We, therefore, recommend that future studies include measurements of T1 relaxation times before and after contrast administration to determine the myocardial extracellular volume fraction and to quantify diffuse MF in addition to LGE-based assessment of focal MF. Also, the use of free-breathing, motion-corrected, averaged LGE CMR measurements may improve image quality of the RV. 52 Use of these novel imaging techniques should further improve our understanding of the development, progression, and clinical interpretation of MF in athletes. 53 reported an association between the number of completed marathons and LGE (P¼.02). Evidence from case reports/series confirms that athletes diagnosed as having MF demonstrate high doses of exercise for many years (Table 1) . For example, an athlete trained 10 h/wk, including 50 km of running and 1 to 2 hours of mountain biking, 32 while another athlete cycled an average of 23,000 km/y for 14 years. 45 These studies and case reports suggest a doseresponse relationship between lifetime exercise exposure and MF development. Indeed, Wilson et al 5 found that the prevalence of MF was the highest (50%) in veteran endurance athletes (mean AE SD age, 57AE6 years) who had been involved in lifelong competitive training for a mean AE SD of 43AE6 years. Studies including predominantly younger participants or less-trained individuals generally fail to find MF. [19] [20] [21] [22] [23] Potential Mechanisms of MF Development Evidence of MF in athletic populations is exclusively based on observational studies, which do not provide insight into potential underlying mechanisms. However, we summarize the available evidence for 4 different pathways based on patient characteristics, location and patterns of MF, and identified predictors.
Factors Associated With MF
Genetic Predisposition. Ten case reports describe the presence of MF in 28 young athletes ( 30 years old). Their young age raises the question whether genetic predisposition contributes to MF development. Hypertrophic cardiomyopathy is the most common genetic heart disease 54 and is associated with a high prevalence of MF. 55 In hypertrophic cardiomyopathy, LGE varies from very limited to large, confluent, infarct-like patches occupying significant proportions of the LV, 56 and it localizes preferentially to the most hypertrophied regions of the ventricle. 54 Furthermore, hypertrophic cardiomyopathy is a frequent cause of sudden cardiac death in young competitive athletes. 57 Mutations in genes coding for sarcomere proteins, Z-disk or calcium-handling proteins, are responsible for the phenotype of hypertrophic cardiomyopathy. 58 However, variability can be so striking in individuals with the same genetic defect that little, if any, relationship can be established between mutations and phenotype, clinical course, and patient outcome. Similarly, genetic factors may contribute to the variability of MF presentations in athletes.
Silent Myocarditis. The results of 5 biopsy studies and 3 CMR-LGE studies suggest that myocarditis is responsible for LGE and that this is probably true in some (n¼10) but not all (n¼65) athletes. Late gadolinium enhancement has high specificity for the detection of injury in myocarditis but variable sensitivity to detect active or chronic inflammation. 59 This might be due to limited areas of necrotic myocytes that cannot be visualized because of limited pixel size in CMR images compared with larger regions of scarring in ischemic necrosis. Myocarditis is defined as inflammatory cellular infiltrate, whereas associated myocyte necrosis may be present on stained heart tissue sections. 60 Myocarditis usually results from infections with viruses such as coxsackievirus B3, adenoviruses, and parvovirus B19 but may also result from other pathogens, such as the protozoan Trypanosoma cruzi (Chagas disease), toxic or hypersensitivity drug reactions (anticonvulsants, antibiotics, and antipsychotics), giant cell myocarditis, or sarcoidosis. 61 Several animal studies found that exercise itself may cause myocarditis and lead to the development of MF. [62] [63] [64] In a rat model of exercise training, MF disappeared after cessation of the exercise. 62 We are unaware of evidence that exercise can produce myocarditis in humans. Many patients with myocarditis have minimal or no symptoms. 65 Despite this, the infection may cause ventricular dilatation or fibrosis. 66 A mouse model found that physical activity during a "silent" myocarditis may exaggerate damage to the heart. 67 Mice were infected with coxsackievirus to induce myocarditis and then were divided into 4 groups: group 1 received immunosuppression with daily doses of cyclosporine and an antithymocyte monoclonal antibody, group 2 performed daily swimming exericise, group 3 received both interventions, and group 4 served as controls. After 21 days, mortality rates were highest in the exercise-only group (group 2). 67 Hence, it is possible that continued exercise training accelerates myocardial damage and MF during a silent myocarditis.
Pulmonary Artery Pressure Overload. The volume of LGE is typically small and confined to the septum or RV insertion points in 48% of athletes diagnosed as having MF by magnetic resonance imaging LGE. This may result from local mechanical stress due to prolonged exercise. Interestingly, MF in this cardiac location is also observed in patients with pulmonary arterial hypertension. 68, 69 Late gadolinium enhancement was present at a similar anatomical location in adults whose RV was forced to produce systemic pressures after atrial redirection surgery for transposition of the great vessels. 70 Focal LGE has been reported at the superior and inferior insertion points of the RV and LV in 36% and 89% of these patients, respectively. 70 Exercise produces a greater relative increase in pulmonic than aortic systolic pressure, resulting in an increase in wall stress of 125% vs 4% for the RV and LV, respectively. 71 The thinner wall of the RV may facilitate the progression from increased wall stress to cardiomyocyte damage more than in the LV. Although echocardiography studies show that acute exercise-induced changes in RV structure and function fully recover within days, 6 chronic structural changes from repetitive prolonged exercise are possible. Therefore, MF in athletes may result from long-term endurance exercise training and competition and the associated repetitive exercise-induced elevations in pulmonary artery pressures.
Repetitive Microdamage. Cardiac troponin I and T are the standard biomarkers used to serologically identify myocardial damage. Many studies have reported increases in cardiac troponin levels after prolonged exercise. 72 Elevated troponin levels were found in 100% of Boston Marathon participants 73 and are directly related to exercise intensity. 74 Exerciseinduced troponin elevations are hypothesized to be benign and to represent reversible cardiomyocyte membrane damage, 3 but they may represent microdamage to cardiomyocytes. Accordingly, repetitive exposure to highintensity endurance exerciseeinduced cardiac microdamage, evidenced by minor troponin level elevations, could lead to MF development after lifelong exercise training, as observed in veteran athletes. 5 Clinical Implications of MF The presence of MF is an important risk factor for adverse cardiac outcomes in clinical populations. 18,75e78 However, the impact of MF on cardiovascular health has not been carefully studied in athletes. Three of 12 German marathon runners with LGE (25%) required revascularization during a mean AE SD of 21AE3 months of follow-up compared with 1 of 90 runners (1%) without LGE (P<.001). 7 Half of the runners with MF, however, had an LGE pattern suggestive of ischemic myocardial injury. The increased risk of MF on adverse outcomes persisted during a mean AE SD of 74AE12 months of follow-up. 79 Runners with coronary events had a higher prevalence of LGE (57%) compared with peers without coronary events (8%; P¼.003), despite comparable mean AE SD 10-year Framingham Risk Scores (7.9%AE 2.3% vs 7.0%AE3.7%). 79 The presence of LGE in this cohort was also associated with higher coronary artery calcification scores (median Agatston coronary artery calcium scores, 192 vs 26; P¼.0046), 53 demonstrating that the increased incidence of cardiovascular events in some runners with LGE is due to atherosclerosis and previous infarction. Other studies in other patients do not support atherosclerosis and previous infarction as the cause of the LGE. Although the German findings suggest a worse prognosis in athletes with MF, it must be emphasized that these data are derived from a single cohort. Nevertheless, athletes with LGE patterns consistent with coronary artery disease and previous infarction or those with evidence of active myocardial inflammation should be pharmacologically treated to reduce their risk of an acute cardiac event and to treat their myocarditis, respectively.
The prognostic significance of nonspecific MF patterns seen in athletes is unknown. There is no evidence that athletes with this pattern should be restricted from exercise. Additional clinical testing should be recommended based on the individual's symptoms and clinical profile. Myocardial fibrosis detected by LGE in cardiac studies of asymptomatic athletes performed for other nonclinical reasons should be treated as an incidental finding and not pursued.
The impact of lifelong exercise training on cardiovascular health is under debate. 3, 80 Although some studies report a U-shaped association between exercise volume and cardiovascular risk, 81, 82 most available evidence suggests a curvilinear relationship, with greater health benefits at larger exercise doses. [83] [84] [85] Furthermore, there is substantial evidence that longevity benefits are most prominent in the most active individuals (ie, elite athletes). 86 Nevertheless, data from CMR athletic population studies suggest that some long-term endurance athletes develop MF.
CONCLUSION
Myocardial fibrosis has been reported in some lifelong endurance athletes. The pattern of LGE is heterogeneous, which may represent different causation and could contribute to the difference in MF locations between case studies/series and athletic population studies. In a few of these athletes, CMR-detected LGE is consistent with coronary artery disease and previous infarction and seems to be associated with increased risk of cardiovascular events. Other middle-aged and older athletes demonstrate LGE largely confined to the interventricular septum, often near the hinge points between the RV and the septum. This pattern seems more common in long-term endurance athletes and may represent the effect of repetitive myocardial microtrauma or repetitive dilatation of the RV with exercise. Athletes with underlying cardiovascular disease should receive pharmacological treatment to reduce the risk of secondary events. The significance of nonspecific MF is largely unknown, and future studies investigating the functional and clinical consequences of MF in athletes are warranted. 
